Table 1.
Baseline characteristics of study participants
| 0·67 mg GLS-5300 (n=25) | 2 mg GLS-5300 (n=25) | 6 mg GLS-5300 (n=25) | Total (n=75) | ||
|---|---|---|---|---|---|
| Sex | |||||
| Male | 14 (56%) | 14 (56%) | 16 (64%) | 44 (58·7%) | |
| Female | 11 (44%) | 11 (44%) | 9 (36%) | 31 (41·3%) | |
| Ethnicity | |||||
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | |
| Asian | 2 (8%) | 2 (8%) | 2 (8%) | 6 (8%) | |
| Black or African American | 10 (40%) | 11 (44%) | 10 (40%) | 31 (41·3%) | |
| Native Hawaiian or Pacific Islander | 0 | 0 | 0 | 0 | |
| White | 13 (52%) | 12 (48%) | 12 (48%) | 37 (49·3%) | |
| Other | 0 | 0 | 1 (4%) | 1 (1·3%) | |
| Hispanic or Latino | 2 (8%) | 0 | 2 (8%) | 4 (5·3%) | |
| Age, years | 33·2 (10·4) | 33·0 (7·7) | 30·5 (9·8) | 32·2 (9·3) | |
| Age range, years | 19–50 | 19–49 | 19–50 | 19–50 | |
Data are n (%), mean (SD), unless otherwise indicated.